Clifford J Bailey Selected Research

Type 2 Diabetes Mellitus (MODY)

2/2024	Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes.
1/2024	Recent advances in peptide-based therapies for obesity and type 2 diabetes.
6/2023	Synthalin: a lost lesson for glucagon suppression in diabetes therapeutics.
1/2023	An update on peptide-based therapies for type 2 diabetes and obesity.
1/2022	Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure.
1/2022	Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
1/2022	Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin.
11/2021	Recent advances in peptide-based therapy for Type 2 diabetes and obesity.
1/2021	Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
1/2021	Real-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Clifford J Bailey Research Topics

Disease

50	Type 2 Diabetes Mellitus (MODY) 02/2024 - 06/2003
15	Obesity 02/2024 - 01/2002
15	Insulin Resistance 01/2022 - 01/2005
7	Body Weight (Weight, Body) 02/2024 - 08/2005
7	Weight Loss (Weight Reduction) 01/2020 - 10/2005
6	Infections 01/2022 - 06/2010
5	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 07/2009
5	Chronic Renal Insufficiency 01/2022 - 12/2014
5	Lactic Acidosis 01/2022 - 12/2014
5	Hypoglycemia (Reactive Hypoglycemia) 01/2021 - 10/2009
5	Weight Gain 01/2017 - 01/2005
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 08/2012
3	Heart Failure 01/2022 - 01/2019
3	Inflammation (Inflammations) 01/2022 - 04/2015
3	Hyperglycemia 01/2021 - 10/2009
3	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2021 - 01/2005
3	Myocardial Infarction 01/2019 - 01/2005
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2019 - 01/2005
2	Acidosis 01/2022 - 01/2018
2	Urinary Tract Infections (Urinary Tract Infection) 01/2022 - 02/2013
2	Atherosclerosis 04/2015 - 01/2005
1	Fibrosis (Cirrhosis) 01/2022
1	Proteinuria 01/2022
1	Metabolic Diseases (Metabolic Disease) 01/2022
1	COVID-19 01/2022
1	Hypotension (Low Blood Pressure) 01/2022
1	Thrombophilia 01/2022
1	Acute Kidney Injury (Acute Renal Failure) 01/2022
1	Disease Progression 01/2022
1	Albuminuria 01/2021
1	Diarrhea 01/2021
1	Diabetes Complications 11/2019
1	Hypertension (High Blood Pressure) 01/2019
1	Stroke (Strokes) 01/2019
1	Ketosis 01/2018
1	Human Influenza (Influenza) 01/2017
1	Kidney Diseases (Kidney Disease) 12/2014

Drug/Important Bio-Agent (IBA)

26	Glucose (Dextrose)FDA LinkGeneric 02/2024 - 11/2002
21	Insulin (Novolin)FDA Link 02/2024 - 01/2002
18	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 06/2003
10	Peptides (Polypeptides)IBA 02/2024 - 11/2002
7	Blood Glucose (Blood Sugar)IBA 02/2024 - 09/2006
6	IncretinsIBA 01/2024 - 12/2003
5	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 09/2005
5	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 02/2011
4	Glucagon-Like Peptide 1 (GLP 1)IBA 02/2024 - 08/2006
4	SodiumIBA 01/2022 - 01/2018
4	gastric inhibitory polypeptide receptorIBA 01/2020 - 08/2005
4	dapagliflozinIBA 11/2019 - 06/2010
4	Hypoglycemic Agents (Hypoglycemics)IBA 01/2019 - 01/2005
3	Glucagon (Glukagon)FDA Link 06/2023 - 12/2003
3	Dipeptidyl-Peptidase IV InhibitorsIBA 11/2019 - 09/2006
3	PalmitatesIBA 12/2009 - 11/2002
3	EnzymesIBA 05/2008 - 11/2002
2	Therapeutic UsesIBA 01/2022 - 01/2020
2	Sodium-Glucose Transport ProteinsIBA 01/2021 - 10/2009
2	LipidsIBA 11/2019 - 04/2015
2	ThiazolidinedionesIBA 01/2019 - 01/2008
2	AdipokinesIBA 11/2017 - 08/2009
2	BiguanidesIBA 01/2017 - 01/2005
2	Insulin ReceptorIBA 04/2015 - 03/2007
2	Sitagliptin Phosphate (Januvia)FDA Link 07/2014 - 08/2010
2	imegliminIBA 07/2014 - 03/2013
2	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 05/2008 - 12/2006
2	Hormones (Hormone)IBA 05/2008 - 12/2003
2	Exenatide (Byetta)FDA Link 01/2008 - 10/2005
1	tirzepatideIBA 02/2024
1	Activins (Activin)IBA 01/2023
1	Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA 01/2023
1	setmelanotideIBA 01/2023
1	bimagrumabIBA 01/2023
1	Monoclonal AntibodiesIBA 01/2023
1	(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triolIBA 01/2021
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2021
1	Glucagon Receptors (Glucagon Receptor)IBA 01/2020
1	Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)IBA 01/2020
1	saxagliptin FDA Link 11/2019
1	AutoantibodiesIBA 11/2019
1	semaglutideIBA 01/2019
1	empagliflozinIBA 01/2019
1	CanagliflozinIBA 01/2019
1	Liraglutide FDA Link 01/2019
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2019
1	omega-Chloroacetophenone (Mace)IBA 01/2019
1	Uric Acid (Urate)IBA 01/2019
1	CreatinineIBA 01/2018
1	E-SelectinIBA 11/2017
1	Phenformin (Fenformin)IBA 01/2017
1	BuforminIBA 01/2017
1	Antimalarials (Antimalarial Agents)IBA 01/2017
1	CeramidesIBA 04/2015
1	CytokinesIBA 04/2015
1	Lactic Acid (Lactate)FDA LinkGeneric 12/2014

Therapy/Procedure

24	Therapeutics 01/2024 - 01/2005
6	Glycemic Control 06/2014 - 10/2005
3	Injections 06/2007 - 09/2005
1	Islets of Langerhans Transplantation 01/2022
1	Cell Transplantation 01/2021
1	Bariatric Surgery 01/2019
1	Surgical Amputation (Amputations) 01/2018